抗真菌
临床试验
抗真菌药
抗真菌药
医学
重症监护医学
皮肤病科
病理
作者
Doaa M. Hanafy,David J. Leaver
标识
DOI:10.1021/acsmedchemlett.4c00568
摘要
The World Health Organization (WHO) fungal priority pathogens list (WHO FPPL) published in 2022 highlighted the inequity and research challenges faced by researchers who study pathogenic fungi that afflict humans. Antifungal drugs are the only weapon available to treat infections; however, these drugs are old, are not effective against multidrug-resistant (MDR) fungal strains, and are associated with substantial toxicity in clinical use. This Microperspective summarizes challenges pertaining to antifungal drug discovery in addition to highlighting recent advances and antifungal agents in clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI